tyrosine-kinase inhibitor

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

November, 2024

tyrosine-kinase inhibitor

Sep 2, 2024, 03:41 | Insight

FDA Grants Zongertinib Breakthrough Therapy Designation in HER2-Mutant NSCLC

The FDA has recently granted Zongertinib, a HER2-specific tyrosine kinase inhibitor (TKI), Breakthrough Therapy Designation…

Apr 14, 2024, 22:26 | Insight

Sergio Cifuentes Canaval: Wu Y-L et al. have just released the results of a preplanned interim analysis from the ALINA trial

Sergio Cifuentes Canaval, Cancer Research Project Manager at CENEIT México, shared a post on LinkedIn:…

Apr 12, 2024, 10:05 | Drugs

Piotr J. Wysocki: Immunotherapy combined with tyrosine-kinase inhibitor is not better than docetaxel in NSCLS patients after first-line chemoimmunotherapy failure

Piotr J. Wysocki, Head of the Oncology Department at the University Hospital Krakow, shared a post…

All: 3 Posts: 1 - 100

ASCO GI 2025 - Everything You Need To Know About Biggest Gastrointestinal cancer Symposium

Side Effects of Radiotherapy: Risks and What to Know

Isabel Rubio has been elected as the President of the European Cancer Organisation for 2026-2027

Dr. Richard Pazdur's 25 Year WAR on Cancer at the FDA!

China Anti-Cancer Association (CACA) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

Special Coverage

ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023